-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Upgrades Rocket Pharmaceuticals to Buy, Announces $9 Price Target

Benzinga·09/16/2026 10:13:55
Listen to the news
Needham analyst Gil Blum upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Hold to Buy and announces $9 price target.